Krystal Biotech, Inc. KRYS
We are a fully integrated, global, commercial-stage biotechnology company focused on the discovery, development, manufacturing and commercialization of genetic medicines to treat diseases with high unmet medical needs. 10-K, Item 1
- Headquarters
- Pittsburgh, PA
- CEO
- Krish S. Krishnan
- Next results
- around Jan 11, 2027
KRYS among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
13 new risk paragraphs and 2 accounting facts worth reading about. 10-K filed Feb 17, 2026 against Feb 19, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
2facts worth reading about the other 9 checks found nothing to note
-
Cash from operations lower than net incomeCash from operations $200.9M vs net income $204.8M (FY ending Dec 31, 2025)
-
Inventory growing faster than revenueInventory +52.7% ($26.5M to $40.5M) vs revenue +33.9% ($290.5M to $389.1M), +18.7 pts apart
-
Receivables +21.7% ($104.7M to $127.4M) vs revenue +33.9% ($290.5M to $389.1M), -12.3 pts apart
8 more checks with nothing to note
-
Same auditor in both 10-Ks: KPMG LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
The same matters as last year: Evaluation of the sufficiency of audit evidence over the Medicaid rebate accrual
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
13 paragraphs in Risk Factors that were not in the 10-K filed Feb 19, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 19, 2025 10-K, ITEM 1A
In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal information privacy laws, consumer protection laws, and other similar laws. Notably, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health…
-
Item 1A · new paragraph · not in the 10-K filed Feb 19, 2025 10-K, ITEM 1A
There remains substantial uncertainty as to how the current U.S. administration will seek to or continue to modify or revise the requirements and policies of the FDA and other regulatory agencies with jurisdiction over VYJUVEK and our
-
Item 1A · new paragraph · not in the 10-K filed Feb 19, 2025 10-K, ITEM 1A
European Commission, MHLW, or other foreign regulators may issue new or revised guidelines concerning the development and marketing authorization of gene therapy medicinal products.
-
Item 1A · new paragraph · not in the 10-K filed Feb 19, 2025 10-K, ITEM 1A
We were granted RMAT designation for B-VEC from the FDA, and we may seek RMAT designation for some of our product candidates. In 2017, the FDA established the RMAT designation as part of its implementation of the 21st Century Cures Act to expedite review of any drug that meets the following criteria: it qualifies as a RMAT, which is…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $0 | $50.7M | $290.5M | $389.1M |
| Net income | −$140.0M | $10.9M | $89.2M | $204.8M |
| Operating cash flow | −$100.6M | −$88.8M | $123.4M | $200.9M |
| Free cash flow | −$153.5M | −$100.6M | $119.2M | $188.9M |
Revenue, FY2021 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$389.1M ▲ 33.9% in FY2025$204.8M ▲ 129.7% in FY2025$188.9M ▲ 58.5% in FY2025
Recent filings
4 filings in the last 30 days · SEC EDGAR
-
Planned saleNov 2, 2026Kathryn Romano (Executive Vice President & Chief Accounting Officer) adopted a 10b5-1 trading plan reported in the 10-Q, up to 1,163 shares, runs to Dec 31, 2027
-
Planned saleNov 2, 2026Laurent Goux (Executive Vice President, Head of International) adopted a 10b5-1 trading plan reported in the 10-Q, up to 3,045 shares, runs to Sep 10, 2027
-
8-KNov 2, 2026Quarterly results 8-K item 2.02
-
10-QNov 2, 2026Quarterly report (10-Q) period ended Sep 30, 2026
About the company
Krystal Biotech, Inc., Pittsburgh, PA · from the 10-K filed Feb 17, 2026
We are a fully integrated, global, commercial-stage biotechnology company focused on the discovery, development, manufacturing and commercialization of genetic medicines to treat diseases with high unmet medical needs. Using our patented gene therapy technology platform that is based on engineered herpes simplex virus-1 (“HSV-1”), we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell’s own machinery then transcribes and translates the transgene to treat the disease.
- Headquarters
- Pittsburgh, PA
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 2, 2026
Email alerts
Sources
The 10-K filed Feb 17, 2026 (open at SEC), compared with the 10-K filed Feb 19, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/KRYS/export.csv") into a cell.